Our Company
Our radiopharmaceuticals utilize novel molecules to precisely deliver targeted radiation to cancer cells for diagnosis and therapy.
-
Our Company
NORROY is a clinical-stage biotechnology company focused on the development and commercialization of innovative therapeutic and diagnostic radiopharmaceuticals, as well as automated synthesis systems and functional modules for radiopharmaceutical manufacturing in both R&D and GMP environments.
Founded in July 2021, NORROY has radiopharmaceutical candidates currently under clinical investigation in more than 10 disease targets across multiple therapeutic areas, including urological oncology, gastrointestinal oncology, and other oncology and non-oncology indications. Beyond innovative radiopharmaceuticals and automated manufacturing solutions, NORROY continues to establish a reliable global supply chain for multiple radioisotopes, build commercial GMP manufacturing facilities, and develop a global distribution network with international partners.
To date, NORROY has received six (6) IND clearances from the FDA and six (6) IND approvals from the National Medical Products Administration (NMPA). The Company is actively working with global regulatory agencies to advance its late-stage programs through internationally registered clinical trials.
Norroy 's Sub Business
Norroy Global Operations
Norroy has established operations not only in Wuxi, Nanjing, Maanshan in China, but also in the United States.
Our state of the art GMP grade and automated radiopharmaceutical production facility in Maanshan is one of the largest of its kind globally and expected to open in 2026 to deliver manufacturing solutions to meet clinical and commercial production requirements nationwide and globally.
Our state of the art GMP grade and automated radiopharmaceutical production facility in Maanshan is one of the largest of its kind globally and expected to open in 2026 to deliver manufacturing solutions to meet clinical and commercial production requirements nationwide and globally.
-
Research & Development Network
- 2x Radiochemistry Development Laboratories, China & United States
- 3x Preclinical Research Centers, China
- 1x Clinical Research Institute, China
- 1x Next Generation Intelligent, Automated Equipment Development Center, China
-
Clinical Network
- 15+ Research Hospitals with active, ongoing IIT&IND clinical trials, China
- 30+ Research Hospitals under negotiation to conduct 2 diagnostic Phase Ⅲ trials & 1 therapeutic Phase Ⅲ trial (pending NMPA approvals), China
- 3+ International Research Hospitals under negotiation (ex-China)
-
-
Norroy Anhui Co. Ltd., China
- 1 Class A GMP commercial production facility under construction (24,000m2)
-
Norroy Bioscience Co. Ltd., China
- 1 Class B GMP facility in operation (supplying clinical trial patient doses)
1 Class B GMP facility in renovation
Contact us - 1 Class B GMP facility in operation (supplying clinical trial patient doses)
-
Norroy Bioscience Nanjing Research Institute, China
- Leveraging regional advantages to build a top-tier radiopharmaceutical R&D platform and drive breakthroughs in theranostic innovation.
Contact us -
Norroy Programs by Disease Areas
Norroy's pipelines focus on unmet medical needs of the patients and healthcare professionals, in the disease areas including urological cancers, gastrointestinal & pancreatic cancers, lung cancers, breast & ovarian cancers, nasopharyngeal cancers, neurological cancers, solid tumors, and other diseases.
